Covid-19 Ivermectin

Uporabnik mosseero je napisal:

Bi morda blagovolil tudi ti prebrat kaj, kar ti ostali serviramo ali se boš samo na nad nosilcem informacij zmrdoval?

Klikni za razširitev

Uporabnik BLABLABLA je napisal:

FULL INTERVIEW: WORLD RENOWNED DOCTOR BLOWS LID OFF OF COVID

FULL INTERVIEW: Dr. Peter McCullough discusses the dangers of the novel COVID vaccine and it's roll out. This is a product that had minimal testing but is being pushed on the masses. Must we all get t

rumble.com

Klikni za razširitev

Lina said that “we have the feeling today that the vaccine induces better immunity than certain natural infections.”

He said that for people with less symptomatic bouts of Covid-19, “we observe a rapid loss of antibody titer, and therefore a potential for reinfection faster than that observed with vaccination.”

The Pasteur Institute’s Schwartz also confirmed that people who have contracted Covid-19 have an interest in being vaccinated “because the antibody level decreases in all people.”

Klikni za razširitev

Uporabnik jest5 je napisal:

Tako kot je boljši odgovor glede protiteles, tako je boljši tudi glede ostalega.
Je pa jasno protitelesa najlažje izmeriti.

Klikni za razširitev

Case study: Policy intervention in Mexico City Increase in COVID-19 cases and with critical levels of hospital saturation during December 2020 Mexico City Government decided to expand population-based health Interventions Implementation of a prehospital home-care program Combining early detection with antigen tests 230 kiosks Phone-based follow up for positive patients Since 28 December, 2020, medical ivermectin kits have been provided to positive mild to moderate symptomatic patients Dyspnea, chest pain or cyanosis, referred to a hospital Ivermectin, four 6mg tablets, two pills for two days After one month, 83,000 medical kits delivered Detailed data was collected on the evolution of patient illnesses Quasi-experimental evaluation of the effects of the medical kits on hospitalization Kit receivers and non-kit receivers Matched observations, adjusting by age, sex, COVID severity, and comorbidities Controls, N = 156,468 patients with COVID-19 infection before implementing the ivermectin program Experimental group, n = 77,381 after the implementation Outcome variable: whether or not the person was hospitalized Results Negative and significant effect of the ivermectin-based medical kit on the probability of hospitalization Effect ranges from 50% to 76% Difference in hospitalization odds between treated and untreated patients, statistically significant in all cases As expected, the effect of the medical kits is higher and stronger among males, in older patients, and in cases without severe symptoms Discussion and limitations we found that the medical kit given en masse to patients who’d tested positive in Mexico City had a negative, significant, and robust effect on their odds of being hospitalized. Independently of the medical telephone follow, level of hospital occupancy, specific period of time Similar trend, Perú (Chamie-Quintero Et Al, 2021). Principal mechanisms, reduction of viral load, in the patients that take ivermectin in early stages of the disease

Klikni za razširitev

25 states of Peru Grouped by extent of IVM distributions Maximal, medium, minimal Reductions in excess deaths (30 days after peak deaths) maximal, 74% medium, 53% minimal, 25% Reduction of excess deaths is correlated with extent of IVM distribution by state p less than 0.002 This strongly suggests that IVM treatments can likewise effectively complement immunizations to help eradicate COVID-19. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Klikni za razširitev

Uttar Pradesh government says early use of Ivermectin helped to keep positivity, deaths low

Claiming that timely introduction of Ivermectin since the first wave has helped the state maintain a relatively low positivity rate despite in its high population density.

indianexpress.com

Uttar Pradesh government, first to have introduced a large-scale “prophylactic and therapeutic” use of Ivermectin Helped the state to maintain a lower fatality and positivity rate as compared to other states Health Department introduced Ivermectin as prophylaxis for close contacts of Covid patients, August 6, 2020 Agra, Dr Anshul Pareek and State Surveillance Officer Vikssendu Agrawal Administered Ivermectin to all RRT team members in Agra None of them developed Covid-19 Despite being in daily contact Despite being the state with the largest population base and a high population density, we have maintained a relatively low positivity rate and cases per million of population Lower positivity and fatality rates may be attributed to the large-scale use of Ivermectin use UP

Klikni za razširitev

Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial

Background Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection. Methods The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3...

www.medrxiv.org

Conclusions There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.

The study is registered at ClinicalTrials.gov NCT 044297411.

Klikni za razširitev

Results Eighty-nine patients were eligible (47 in ivermectin and 42 in placebo arm). Their median age was 35 years. Females accounted for 21·6%, and 16·8% were asymptomatic at recruitment. Median time from symptom onset was 4 days. There were no statistical differences in these parameters between the two groups.

On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/ 42 (50%) in the placebo arm (OR 2·62; 95% CI: 1·09-6·31). In a multivariable logistic-regression model, the odds of a negative test at day 6 was 2.62 time higher in the ivermectin group (95% CI: 1·06–6·45). Cultures at days 2 to 6 were positive in 3/23 (13·0%) of ivermectin samples vs. 14/29 (48·2%) in the placebo group (p=0·008).

Klikni za razširitev

Tamil Nadu adds all-time high 20,768 new Covid-19 cases; 153 deaths​

Tamil Nadu on Sunday reported a all-time high of 20,768 new COVID-19 cases pushing the caseload to 12,07,112 while the death toll rose to 14,346 with 153 fatalities, according PTI.

According to the Health department, recoveries mounted to 10,72,322 Sunday with 17,576 patients being discharged, leaving 1,20,444 active cases.

The number of samples tested stood at 1,43,083, pushing the cumulative number of specimens examined so far to 2,29,56,942.

Klikni za razširitev